Radico Khaitan's Rampur Distillery Unveils Ankahi Zaffran Spiced Liqueur at the ProWein 2025 in Düsseldorf, Germany
Radico Khaitan Limited (NSE: RADICO) Rampur Distillery is proud to unveil Ankahi Zaffran Spiced Liqueur, the first release in the Ankahi Liqueur series. Making its highly anticipated debut at ProWein 2025 in Düsseldorf, Germany, from March 16th to 18th.
Ankahi Zaffran Spiced Liqueur will be available in two sizes: a 1L bottle for Global Travel Retail and a 700ml bottle for the global market. Shipments will begin in April 2025, with distribution in key markets across the USA, Europe, Asia Pacific, and the Middle East, available at leading liquor retailers and duty-free shops worldwide.
Mr. Sanjeev Banga, President of International Business at Radico Khaitan says, 'Our vision is to take India to the world and share the hidden and forgotten gems of India with the global audience. Ankahi Zaffran Spiced Liqueur is a step in this direction. It represents the fusion of India's heritage and the artistry of liqueur-making. The introduction of this exceptional product at ProWein 2025 marks a significant moment for Radico Khaitan. We are thrilled to share this unique creation with the world, reflecting our commitment to innovation, quality, and sustainability while offering global consumers an authentic taste of India.'
Ankahi Zaffran Spiced Liqueur
At the heart of India's ancient landscapes lie untold stories, waiting to be uncovered. From the verdant valleys of Kashmir comes Ankahi Zaffran Spiced Liqueur, a masterpiece that captures the essence of these hidden tales. Crafted with meticulous artistry, Ankahi blends India's rare herbal treasures into every drop, offering a powerful sensory journey through its rich, timeless heritage.
Essence of Zaffran
Zaffran, the heart of this liqueur, honors Kashmir's golden saffron fields. Known as the jewel of spices, saffron adds vibrant color and unique flavor, balanced by 21 handpicked herbs like clove, cardamom, cinnamon, star anise, and coriander. The result is a complex, inviting spiced herbal liqueur, offering a rare and enchanting experience.
Story Behind the Bottle
Ankahi, meaning 'untold,' embodies the spirit of discovery, unveiling India's hidden herbal treasures. The liqueur's distinctive bottle design symbolizes the revelation of secrets, inviting you to explore the mysteries within. Ankahi Zaffran Spiced Liqueur fuses history, tradition, and India's rich botanical heritage in every drop, celebrating the art of liqueur-making. The carefully chosen herbs, including tulsi (holy basil), mint, and saffron, represent India's deep-rooted traditions and healing practices. These herbs are not only selected for their complex flavors but for their powerful cultural and historical significance in India's herbal legacy.
Mr. Kunal Madan, Senior Vice President of International Business at Radico Khaitan shares, 'Ankahi Zaffran Spiced Liqueur is a celebration of India's rich heritage and botanical legacy. We've carefully crafted this exceptional liqueur to offer a distinctive sensory experience that embodies the untold stories of India. Ankahi is more than just a drink – it's a journey through the vibrant culture and ancient traditions of India, now brought to life for the world to discover.'
Tasting Profile
Nose:
Rich, floral aroma of saffron with a hint of sweetness
Subtle spice from cinnamon and cardamom
Light herbal notes from mint and coriander
Palate:
Bold, floral saffron flavor that takes center stage
Warm, spiced undertones of cinnamon and cardamom
Gentle sweetness from natural botanicals, balancing the spices
Mint and earthy coriander add depth and complexity
Finish:
Smooth and lingering, leaving a warm, spicy sensation on the palate
Complex depth that evolves with every sip, highlighting the herbal richness
Long-lasting, offering a final hint of saffron and spice that gently fades
About Radico Khaitan Limited, was established in 1943, is one of the oldest and largest Indian beverage alcohol companies. Over the years, the company has built a robust brand presence both domestically and internationally. With a steadfast commitment to quality and innovation, Radico Khaitan has successfully expanded its reach, now exporting its diverse portfolio of brands to over 100 countries. The company's products are also available in more than 40 travel retail locations, further solidifying its position as a key player in the global spirits market.
The luxury portfolio includes Rampur Select, Rampur PX Sherry Cask, Rampur Double Cask, Rampur Asava, Rampur Signature Reserve, Rampur Jugalbandi Series, Rampur Trigun Indian Single Malt Whisky, Sangam World Malt Whisky and Jaisalmer Indian Craft Gins.
Two of Radico Khaitan's distilleries are located in Uttar Pradesh in the foothills of the Himalayas, where all of their Malt is distilled, matured and bottled.
About Rampur Distillery, a flagship brand of Radico Khaitan, is renowned for producing premium Indian single malt whisky. Nestled in the foothills of the Himalayas, the distillery is deeply rooted in the rich heritage and craftsmanship of Indian whisky-making. By blending traditional methods with modern techniques, Rampur Distillery creates exceptional whiskies that appeal to discerning connoisseurs worldwide. Its offerings, including Rampur Indian Single Malt and Rampur Barrel Blush, have earned international acclaim for their unique flavor profiles and remarkable smoothness, establishing Rampur as a standout in the global spirits market.
About ProWein 2025, is one of the world's leading trade fairs for the wine and spirits industry. Held annually in Düsseldorf, Germany, this prestigious event brings together industry professionals, producers, distributors, and retailers from around the globe. ProWein 2025, taking place from March 16th to 18th, will showcase the latest trends, innovations, and premium products from the world of wine, spirits, and beverages. It serves as a significant platform for networking, business development, and discovering new opportunities in the global beverage market.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
HGS appoints Venkatesh Korla as Global CEO
AUSTIN, Texas, June 11, 2025 /PRNewswire/ -- Hinduja Global Solutions (HGS) (listed on BSE & NSE), a leading provider of digital experience, business process management (BPM), and digital media services, has announced the appointment of Mr. Venkatesh Korla as the new Global CEO of HGS. The HGS Board approved the elevation of Venkatesh, formerly President & CEO of HGS Americas, to the role of Global CEO, effective May 28, 2025. He succeeds Mr. Partha DeSarkar, who has been at the helm of the company since 2006 and is expected to retire in September 2025. Venkatesh is an accomplished business leader with 25+ years of experience in core digital services and tech-enabled customer experience (CX). He has an impressive track record of growing high-performance teams globally and fostering lasting client relationships. In his earlier stints, he has been part of organizations providing expert consultation on digital strategies and solutions to Global 1000 companies, healthcare institutions, universities, and not-for-profit organizations. He also founded Element Solutions, later acquired by HGS and now forms the foundation of HGS' tech services business, that delivers strategic consulting, data analytics, marketing technology, intelligent automation, and cloud solutions to clients across the private and public sectors. Mr. Ashok P. Hinduja, Chairman, HGS said, "The company is currently evolving to align towards an AI-led future in line with the technology changes in the market and evolving client needs. Venkatesh, with his deep expertise and proven track record of leading digital transformation at scale, is the right person to lead HGS' future growth with a digital approach. On behalf of the Board, I would like to congratulate him and am looking forward to collaborating on the new journey ahead." Speaking on his elevation as the new Global CEO, Venkatesh Korla said, "It is a tremendous honor to take on the role of Global CEO at HGS. I step into this position with deep respect for the legacy we've built so far, led by the strong leadership of Partha DeSarkar, and a sense of great excitement for how we can shape the future. Our people are our greatest strength, and by combining their passion with the power of technology, we will create meaningful, human-centered solutions that redefine how we serve our clients and their customers, and accelerate our journey as a digitally-led organization." Photo - - View original content to download multimedia: SOURCE Hinduja Global Solutions Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
7 hours ago
- Business Upturn
NSE gets SEBI nod to launch monthly electricity futures, aims to deepen power market reforms
By News Desk Published on June 11, 2025, 19:21 IST The National Stock Exchange of India (NSE) has received regulatory approval from the Securities and Exchange Board of India (SEBI) to launch monthly electricity futures contracts, marking a significant milestone in India's efforts to deepen its power markets and drive long-term structural reforms under the Electricity Act, 2003. The new futures contracts will provide market participants with tools to hedge against electricity price volatility, offer more accurate price signals, and encourage capital investment across the electricity value chain, including generation, transmission, distribution, and retail. According to Niti Aayog, India's transition to net-zero emissions by 2070 will require over $250 billion in annual investment until 2047, with more than 50% of installed power capacity expected to come from solar and wind by 2030. A liquid electricity derivatives market is seen as critical for attracting large-scale domestic and international climate finance. NSE MD & CEO Ashishkumar Chauhan stated that the approval is 'only the beginning' of the exchange's broader electricity derivatives strategy. Future offerings could include contracts for difference (CFDs) and longer-duration contracts like quarterly and annual futures, subject to regulatory clearances. The contracts will be financially settled and cleared by NSE Clearing Limited, a SEBI-recognized Qualified Central Counterparty (QCCP) with a robust settlement mechanism and strong capital base. NSE was the first Indian exchange to enter the electricity space, having established Power Exchange India Limited (PXIL) in 2008. With its combined expertise in spot and derivatives markets, NSE aims to build a comprehensive and liquid electricity derivatives ecosystem, aligned with key policy initiatives like Market-Based Economic Dispatch (MBED) and market coupling by CERC. This development strengthens NSE's position as a global leader in derivatives, having been ranked the world's largest derivatives exchange by trading volume in 2024 by the Futures Industry Association (FIA). News desk at
Yahoo
10 hours ago
- Yahoo
Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.
Funding supports pivotal Phase 3 trial for sovateltide, a potential first-in-class therapy that could transform the treatment of acute cerebral ischemic stroke WILLOWBROOK, Ill., June 11, 2025 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz" or the "Company"), a late-stage biopharmaceutical company developing innovative therapies for unmet medical needs in critical care and neurology, has announced a $25 million equity investment from Sun Pharmaceutical Industries Limited (Reuters: Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies), one of the world's leading pharmaceutical companies. This strategic investment brings Sun Pharma's total commitment in Pharmazz to $40 million (including a previous $15 million equity investment). 'We believe sovateltide has the potential to redefine the treatment of ischemic stroke, which has not seen a new FDA approved non-thrombolytic therapy in over 30 years. This investment means we are now fully funded to complete our pivotal Phase 3 study and execute on our mission to make this first in class therapy available to stroke patients,' said Emeritus Prof. Anil Gulati, CEO and Founder of Pharmazz. 'We deeply value Sun Pharma's continued partnership, which strengthens our ability to bring our therapies to patients worldwide.' The new funding will provide Pharmazz with the capital required to complete the pivotal U.S. Phase 3 clinical trial of sovateltide (known as Tycamzzi® and Tyvalzi™ in international markets), its lead drug candidate for treating acute cerebral ischemic stroke. Dr. Neil Marwah, President of Pharmazz, added, 'This investment gives us the operational runway to execute a complex, multi-country clinical trial and scale the company responsibly as we prepare for a potential public offering. We are thrilled to strengthen our partnership with Sun Pharma, whose continued support reflects deep confidence in our platform and our ability to execute.' Phase 3 Trial of Sovateltide for Stroke Covered by Special Protocol Assessment Sovateltide is a first-in-class endothelin-B receptor agonist to treat acute cerebral ischemic stroke that can be administered up to 24 hours after the onset of symptoms. Pharmazz has received agreement from the US Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the study design and statistical analysis plan of its Phase 3 clinical trial of sovateltide for the treatment of acute cerebral ischemic stroke patients. Pharmazz is initiating the Phase 3 RESPECT-ETB ( ID: NCT05691244) trial at 65 sites in the US, Germany, Spain, and the UK, designed to enroll 514 stroke patients. The primary endpoint is the proportion of patients demonstrating functional independence post-stroke, defined as a modified Rankin Scale (mRS) score of 0–2 at 90 days after stroke onset. Commercially Approved in India: Early Validation from 60,000+ patients Sovateltide was approved in 2023 in India and marketed by Sun Pharma under the brand name Tyvalzi™, offering compelling proof of concept for global commercialization. In a randomized, placebo-controlled, multicenter clinical trial conducted in 158 cerebral ischemic stroke patients conducted in India, the product was shown to be well tolerated and effective in improving neurological outcomes when administered within 24 hours of stroke symptoms. Patients on Sovateltide were 22.7% more likely to achieve functional independence at 90 days (as measured by mRS score 0–2; p=0.0045) Sovateltide delivered a 17.1% higher rate of favorable National Institutes of Health Stroke Scale (NIHSS) scores (p=0.0024) The ordinal shift in mRS and NIHSS score between control and sovateltide groups was favorable towards sovateltide across the entire range. Results represent the first statistically significant clinical data in stroke in 30 years, since the introduction of alteplase (tPA) Over 60,000 patients treated to date since commercial launch in India Targeting a Multibillion-Dollar Market with a Broader Therapeutic Window Stroke remains one of the leading causes of disability and death globally, with over 7 million ischemic strokes annually. Today, fewer than 15% of patients receive approved interventions, largely due to their narrow treatment window and strict eligibility criteria. Sovateltide's 24-hour dosing window and broader eligibility could expand access—particularly for underserved populations—and position it as a major advance in acute stroke care. If successful in Phase 3 and subsequently approved, sovateltide has strong commercial potential and is expected to be a foundational product in the Pharmazz emerging neurology franchise. About Sovateltide Sovateltide is a first-in-class drug to treat acute cerebral ischemic stroke, a condition in which the loss of blood supply to the brain prevents brain tissue from receiving oxygen and nutrients, resulting in potential brain damage, neurological deficits, or death. Sovateltide is unique because its action site is the neural progenitor cells. Sovateltide promotes neurovascular remodeling by forming new neurons (neurogenesis) and blood vessels (angiogenesis). Sovateltide also protects neural mitochondria and enhances their biogenesis. About Pharmazz, Inc. Pharmazz is a privately held company developing novel products in critical care medicine. Pharmazz, Inc. obtained marketing authorization for two of its first-in-class drug molecules, centhaquine and sovateltide, for hypovolemic shock and ischemic stroke, respectively, in India. In addition, the US Food and Drug Administration (FDA) has approved two phase III INDs for centhaquine as an agent for hypovolemic shock and sovateltide for cerebral ischemic stroke. Additional information may be found on the Company's website, About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050): Sun Pharma is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. and global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and oncodermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit Disclaimer: Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. Contacts: Pharmazz, Inc. Investors Kabir Marwah MediaShruti Gulati Tel +1 630 780 6087 Tel +1 630 780 6087 E mail E mail produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
